Additional trials of Dermagraft to start:
This article was originally published in Clinica
The FDA has given Advanced Tissue Sciences (ATS) permission to begin additional trials of its Dermagraft skin replacement product for treating diabetic foot ulcers. The US agency told ATS in June that it must start a new trial of the skin before it can be approved (see Clinica No 812, p14). The new trial will include up to 30 centres and will involve 330 patients over 18 months. However, if an interim study of 180 treatments shows results equivalent to the previous PMA trial, the new trial could be stopped after one year.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.